- Senseonics (SENS, Financial) sees revenue growth in Q4 2024, buoyed by the Eversense 365 system.
- Analyst forecasts indicate significant potential upside, with price targets ranging from $0.30 to $2.00.
- Despite revenue growth, Senseonics reports a net loss for the quarter.
Senseonics Holdings Inc (SENS) has recently reported a notable performance for the fourth quarter of 2024. The company's revenue reached $8.3 million, reflecting a modest increase from $8 million in the prior year. This growth is primarily attributed to the successful release of the FDA-approved Eversense 365 glucose monitoring system. Although gross profit improved due to enhanced margins, the company still recorded a net loss of $15.5 million.
Wall Street Analysts' Forecast
Market experts remain cautiously optimistic about Senseonics Holdings, with analyst forecasts presenting a range of future price targets. Two analysts have projected a one-year average target price of $1.15, with estimates spanning from a low of $0.30 to a high of $2.00. This suggests a potential upside of 90.87% from the current price of $0.60. For more in-depth analysis, visit the Senseonics Holdings Inc (SENS, Financial) Forecast page.
The consensus among five brokerage firms is a "Hold" status for Senseonics, with an average brokerage rating of 3.0 on their scale. This rating system ranges from 1 to 5, where 1 signifies a Strong Buy and 5 represents a Sell recommendation.
Further supporting the bullish outlook, the GF Value tool by GuruFocus estimates Senseonics' fair value at $1.24 in the coming year, suggesting an impressive upside of 105.81% from the current share price of $0.6025. The GF Value considers historical trading multiples, past business growth, and future business performance projections. More comprehensive data is available on the Senseonics Holdings Inc (SENS, Financial) Summary page.
